Table 1.

NCI-WG response and progression-free survival by pretreatment characteristics

Patient characteristic	n	% CR	% ORR	Median PFS, mo
Overall	60	70	92	38
Age, y
< 60	33	70	88	32
61-70	27	70	96	38
Sex
Male	45	64	89	32
Female	15	87	100	38+
Rai stage
I-II	30	70	90	32
III-IV	30	70	93	42+
ECOG PS
0	13	69	85	32
1-2	47	70	95	38+
WBC, ×109/L
≤ 50	17	70	88	42+
51-150	25	72	92	32
> 150	18	68	94	28
β2-microglobulin, mg/L
4-5.0	26	69	96	38
> 5.0	34	70	88	42+
LDH
< 1.5× ULN	40	67	92	42+
> 1.5× ULN	20	75	90	32
IGHV gene status
Mutated (> 2%)	20	70	100	42+
Unmutated (< 2%)	37	73	92	32
Unavailable	3	33	33	32
Cytogenetics by FISH
17p deletion	14	57*	78*	15*
11q deletion	10	80	90	27
Trisomy 12	15	93	100	42+
None	10	50	90	42+
13q (sole) deletion	11	64	100	42+
CD38 expression
≤ 30%	39	62	94	38
> 30%	21	86	90	28*
ZAP 70 (by IHC)
Positive	33	57*	82	32
Negative	16	94	100	42+
Unavailable	11	73	91	38

P < .05.

NCI-WG indicates National Cancer Institute–Working Group; CR, complete remission; ORR, overall response rate; PFS, progression-free survival; ECOG, Eastern Cooperative Oncology Group; PS, performance status; LDH, lactate dehydrogenase; IHC, immunohistochemistry; ULN, upper limit of normal; and +, median not reached.